Institutional investors purchased a net $4.3 million shares of ATHX during the quarter ended December 2012 and now own 21.42% of the total shares outstanding. This is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
| Individual stakeholders | 6.18% |
| Other institutional | 20.83% |
| Mutual fund holders | 0.59% |